Direxion Daily COIN Bull 2X ETF (CONX)

Direxion is sharpening its focus on the fast-moving, high-conviction corner of the market with the launch of five new single-stock daily leveraged and inverse ETFs packaged for traders who thrive on speed, volatility, and laser-focused thematic bets.

CONX acquires a controlling interest in RED Technologies, a uniquely positioned "enabler" of Shared Spectrum and the nascent Private Network industry CONX appoints Marc Rouanne to the RED Technologies board LITTLETON, Colo. , Dec. 5, 2024 /PRNewswire/ -- CONX CORP.

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of CONX Corp. CONX Corp.'s securities were suspended on May 6, 2024, and have not traded on Nasdaq since that time.

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced CONX Corp. (OTCQX: CNXX; CNXXW) has qualified to trade on the OTCQX® Best Market. CONX Corp. previously traded on NASDAQ.

LITTLETON, Colo. , May 1, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX"), completed its previously announced transaction pursuant to the terms of the purchase and sale agreement (as amended by that amendment to the sale and purchase agreement, the "Purchase Agreement"), dated as of March 10, 2024, by and between the Company and EchoStar Real Estate Holding L.L.C.

LITTLETON, Colo. , April 29, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX") announced today the final results of its previously announced tender offer (the "Tender Offer") to purchase up to 2,120,269 of its shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), at a purchase price of $10.598120 per share.

LITTLETON, Colo. , April 15, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX") announced today that it has changed the price to be paid in its previously announced tender offer (the "Tender Offer") to purchase up to 2,120,269 of its shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), to $10.598120 per share (the "Purchase Price").

LITTLETON, Colo. , April 1, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX") announced today that it has commenced a tender offer (the "Tender Offer") to purchase up to 2,120,269 of its shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), at a purchase price of $10.585614 per share (the "Purchase Price").

LITTLETON, Colo. , Oct. 12, 2022 /PRNewswire/ -- CONX, Corp. (Nasdaq: CONX, CONXU, CONXW) ("CONX" or the "Company") encourages stockholders to vote in favor of the proposal to amend CONX's articles of incorporation (the "Extension Amendment") to extend the date by which the Company must complete a business combination from November 3, 2022 to June 3, 2023 (the "Extension").

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX), a worldwide developer and marketer of diagnostic test kits, announced it has received U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) of its ReEBOV™ Antigen Rapid Test. The test is to be used for the presumptive detection of Ebola Zaire virus (detected in the West Africa outbreak in 2014) in individuals with signs and symptoms of Ebola virus infection in conjunction and with epidemiological risk factors (including geographic locations with high prevalence of Ebola infection.) The Corgenix Ebola rapid test is the first rapid diagnostic test (RDT) and the first immunoassay authorized for emergency use by the FDA for the presumptive detection of Ebola virus. The EUA allows the use of the ReEBOV™ Antigen Rapid Test in circumstances when use of a rapid Ebola test is determined to be more appropriate than use of an authorized Ebola nucleic acid (molecular) test, which has been demonstrated to be more sensitive in detecting the Ebola Zaire virus. The authorized ReEBOV™ Antigen Rapid Test is not intended for use for general Ebola virus infection screening, such as airport screening or contact tracing. Unlike molecular testing, which in West Africa can still take days to return results from central testing laboratories, the Corgenix RDT is a point-of-care test that can be used in any clinical facility adequately equipped, trained and capable of such testing, or in any field laboratory with trained personnel capable of such testing, to diagnose suspected Ebola cases in 15-25 minutes. The U.S. regulatory authorization follows last week’s World Health Organization (WHO) listing for procurement for the Corgenix Ebola RDT, making this test available to the health care community worldwide. “The FDA and WHO have been working closely with us throughout this process to get this new test in the hands of those battling on the front lines of the Ebola outbreak as quickly as possible,” said Douglass Simpson, Corgenix President and CEO. “Completing this product development in less than a year demonstrates how governmental agencies, regulatory bodies, industry, non-profits and others can work together to find solutions to catastrophic events such as the Ebola virus outbreak. This collaboration has enabled us to quickly deliver this critically important point-of-care test and potential breakthrough in the fight against Ebola in the current outbreak in West Africa.” Ebola is indigenous to Africa and is one of the deadliest viruses in the world, with mortality rates of between 30 and 90 percent. Ebola and other viral hemorrhagic fevers are difficult to discriminate because many of the early signs and symptoms are nonspecific and common to other infectious diseases such as Dengue fever, Lassa fever, typhoid and malaria. “Corgenix’s work is crucial to addressing the Ebola outbreak in West Africa,” said United States Senator from Colorado Michael Bennet. “This new test has the potential to help medical officials in the field diagnose Ebola virus disease quicker than before to help control the spread of this vicious disease. We're extremely grateful that this Colorado-based company has invested its resources and completed this research to develop such a valuable tool.” The ReEBOV™ Antigen Rapid Test was developed by Corgenix in cooperation with additional members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University, including Autoimmune Technologies LLC, Zalgen Labs LLC, The Scripps Research Institute and the University of Texas Medical Branch at Galveston, as well as other collaborators in West Africa. Mr. Simpson noted, "We are pleased to be part of the VHFC. This is a remarkable group of scientists who have been in the forefront of research in Ebola, Lassa fever and other dangerous viral diseases in Africa for many years. A key component of our success is a result of the commitment and participation of the Ministry of Sanitation and Public Health of the Republic of Sierra Leone and the dedicated medical personnel of the Kenema Government Hospital in Kenema, Sierra Leone, a number of whom have died fighting the current Ebola outbreak.” “This has the potential to be a game-changer in stopping the spread of the epidemic,” said Dr. Robert Garry, Professor of Microbiology and Immunology at Tulane, and Principal Investigator of the VHFC. “Instead of taking days for lab results, the Ebola RDT uses a drop of blood from a finger prick to deliver a diagnosis in as little as 15 – 25 minutes, potentially allowing trained public health workers to isolate and treat patients immediately. Medical personnel will be able to quickly identify hotspots and may prevent resurgence of cases in the current outbreak.” The FDA’s emergency use authorization of the ReEBOV™ Antigen Rapid Test is for the presumptive detection of Ebola viruses (including Ebola Zaire virus detected in the West Africa outbreak in 2014) in individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors, including geographic location with high prevalence of Ebola infection. The test was also evaluated under WHO’s Emergency Use Assessment and Listing procedure, which provides independent technical information on safety, quality and performance of in vitro diagnostics, principally to other United Nations (UN) agencies but also to WHO Member States and other interested organizations in the context of the Ebola emergency. Mr. Simpson stated that the VHFC will remain actively engaged in efforts to advance additional diagnostic products, some already under development for viral and parasitic diseases, and to expand collaborations with global health care partners, including providers in West Africa. The consortium has already developed a suite of additional laboratory assays to complement its RDTs. These additional assays are being developed to permit confirmation of point-of-care test results and augment much needed serosurveillance capabilities via ongoing and future seroprevalence studies on both Ebola and Lassa fever. Development of the Corgenix ReEBOV™ Antigen Rapid Test for Ebola was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) (grants 1R43AI088843 and 2R44AI088843). Additional support has been provided by The Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2003 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). About the Viral Hemorrhagic Fever Consortium The Viral Hemorrhagic Fever Consortium was established as a result of numerous multi-year grants and contracts awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to support Tulane's ongoing efforts to diagnose, treat and prevent Lassa fever. The VHFC expanded its work into Ebola in 2010. The goal of the Consortium is to understand mechanisms related to the human immune response to viral infection. Specifically, by understanding what parts of the virus are recognized by the immune system, scientists can better understand mechanisms of antibody-mediated protection or pathogenesis in humans with Lassa fever, Ebola, and similar diseases. Consortium efforts have focused on the development of new recombinant proteins for diagnostic products, which have shown to be extremely effective in clinical settings in Africa. This progress is allowing a transition of efforts towards instituting better treatment of affected individuals and ultimately prevention of Lassa fever, Ebola, and other diseases altogether. The Consortium is a collaboration between Tulane, The Scripps Research Institute, the Broad Institute, Harvard University, the University of California at San Diego, the University of Texas Medical Branch at Galveston, Autoimmune Technologies LLC, Corgenix Medical Corporation, Zalgen Labs LLC, the Kenema Government Hospital (Sierra Leone), the Irrua Specialist Teaching Hospital and the Redeemer's University Hospital (Nigeria), and various other partners in West Africa. More information is available at www.vhfc.org. Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded two grants totaling $818,000 to advance the development of an Ebola rapid diagnostic test kit. The grants were awarded to Corgenix by the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation. Corgenix has selected three subcontractors to assist on the project: Tulane University, Autoimmune Technologies, LLC and Zalgen Labs, LLC. “The scope and seriousness of Ebola virus outbreaks have resulted in an increased urgency to bring testing and products to market as soon as possible,” said Douglass Simpson, Corgenix president and CEO. “We thank the Gates and Allen foundations for their support and commitment to our efforts to accelerate the development of a rapid test.” The Corgenix point-of-care test kit currently under development is designed to be used in any clinical or field lab to determine in a matter of minutes if a patient is infected with Ebola. Corgenix and the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH, have already developed the ReLASV® rapid test for the Lassa fever virus. The Lassa product is CE marked as a diagnostic test, enabling its use as a diagnostic product in Europe and other countries that recognize the European standard. “Accurate, rapid, point-of-care testing will be critical to helping contain future Ebola and Lassa virus outbreaks,” said Robert Garry, Ph.D., professor of Microbiology and Immunology at the Tulane University School of Medicine. “This grant will help ensure that our consortium develops this diagnostic testing tool as quickly as possible.” Current testing for the Ebola virus requires special biohazard handling and sending test samples long distances to special labs – a process that takes several days. This results in a critical loss of time to diagnose, treat and help prevent the spread of the virus. Development of the Corgenix Ebola test would enable rapid response to public health and bioterrorism threats posed by the deadly virus. The Corgenix Ebola products are not currently cleared or approved by any regulatory authority for diagnostic use. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX.OB) (the “Company”) announced today that it has entered into a memorandum of understanding with plaintiffs’ counsel in the consolidated Nevada putative shareholder class action lawsuit described in the Company’s definitive proxy statement dated October 21, 2014, as supplemented (the “Proxy Statement”), in connection with the Company’s proposed merger with an affiliate of Orgentec Diagnostika (the “Merger”). The memorandum of understanding contemplates that the parties will enter into a stipulation of settlement with respect to the action. The stipulation of settlement will be subject to customary conditions, including court approval. Pursuant to the memorandum of understanding, the Company will file with the U.S. Securities and Exchange Commission (“SEC”) additional materials that supplement the Proxy Statement. In order to allow shareholders time to review the supplemental proxy materials, the Company also announced today that it has decided to convene the special meeting scheduled for 9:00 a.m, Mountain Time, on November 20, 2014, but then immediately adjourn it, without a vote being taken on the Merger and the merger agreement, until 9:00 a.m., Mountain Time, on December 10, 2014. The meeting on November 20, 2014, and the reconvened meeting on December 10, 2014, will each be held at the Westin Westminster, 10600 Westminster Blvd, Westminster, CO 80020. Only shareholders of record at the close of business on October 14, 2014, the record date for the special meeting, are entitled to vote. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). Additional Information about the Merger and Where to Find It This document may be deemed to be solicitation material with respect to the Merger. In connection with the Merger, the Company has filed the Proxy Statement and may file or furnish other relevant materials with the SEC. THE COMPANY’S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY ALL RELEVANT MATERIALS FILED OR FURNISHED WITH THE SEC, INCLUDING THE PROXY STATEMENT, BECAUSE THESE MATERIALS CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The Proxy Statement and other relevant materials (when they become available), and any and all documents filed or furnished by the Company with or to the SEC, may be obtained free of charge at the SEC’s web site at www.sec.gov. In addition, the Company’s investors and security holders may obtain free copies of the documents filed or furnished by the Company with or to the SEC by directing a request to the Company’s proxy solicitor, Georgeson Inc. at (877) 278-4751. Participants in the Solicitation The Company and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of the Company with respect to the Special Meeting. Information about those executive officers and directors of the Company and their ownership of the Company’s common stock is set forth in the Company’s Proxy Statement, and is supplemented by other public filings made, and to be made, with the SEC by the Company. Information regarding the direct and indirect interests of the Company, its executive officers and directors and other participants in the solicitation is set forth in the Proxy Statement. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS We caution you that this document contains disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about us and the merger. All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations, markets for stock, and our evaluation of strategic alternatives, including the merger, are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as ‘‘expect,’’ ‘‘believe,’’ ‘‘anticipate,’’ ‘‘intend,’’ or similar expressions. These forward-looking statements are based upon information presently available to our management and are inherently subjective, uncertain and subject to change, due to any number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements in this document include, but are not limited to, unanticipated delays; the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the outcome of any litigation that has been or may be instituted with respect to the merger; and the inability to complete the merger due to the failure to obtain the approval of our shareholders of the adoption of the Merger Agreement or the failure to satisfy other closing conditions, as well as other risk factors detailed in our Annual Report on Form 10-K for the year ended June 30, 2014, filed with the SEC on September 10, 2014, under the captions ‘‘Forward Looking Statements’’ and ‘‘Risk Factors’’ and otherwise in our reports and filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to control or predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date that they are made. We assume no obligation to update, revise or correct any forward-looking statements after the date of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information, future events or otherwise, except as otherwise may be required by law.

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at approximately $2.2 million versus approximately $2.9 million for the same quarter in the previous year. In addition, due to the lower revenues and the expenses related to the pending strategic merger with Orgentec Diagnostika, the Company incurred a net loss for the period of approximately $770,000 versus net income of approximately $84,000 for the same quarter in the previous year. “The first quarter weakness resulted from a slow down in demand from a major customer for our Aspirin Works product and contract manufactured end products,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “The Company also incurred approximately $600,000 in expenses associated with its review of strategic alternatives and definitive agreement to be acquired by Orgentec Diagnostika.” The Company expects to release its complete financial results for the recently ended quarter on or about November 7, 2014. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements about the Company’s financial outlook and expected results for the first quarter of 2015. These forward-looking statements are based on the Company’s expectations and assumptions, as of the date such statements are made. These forward-looking statements are based upon information presently available to the Company’s management and are inherently subjective, uncertain and subject to change, due to any number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements in this document include, among others, the risk factors detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 17, 2014 under the captions “Forward Looking Statements” and “Risk Factors” and otherwise in the Company’s reports and filings with the Securities and Exchange Commission. Many of these factors are beyond the Company’s ability to control or predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date that they are made. The Company assumes no obligation to update, revise or correct any forward-looking statements after the date of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information, future events or otherwise, except as otherwise may be required by law.

DENVER--(BUSINESS WIRE)--Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year’s outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 million National Institutes of Health (NIH) grant in June. In the past, Corgenix has served as a subcontractor to Tulane University for several NIH-funded grants and contracts related to development of diagnostics, vaccines and therapeutics for hemorrhagic fever viruses such as Lassa, Ebola and Marburg. Corgenix currently serves as the principal investigator for the new NIH-funded three-year contract to complete the development of recombinant diagnostic tests for Ebola. The most recent grant was awarded to Corgenix and members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University. The NIH phase II, R44 grant was awarded to Corgenix and VHFC to develop rapid diagnostic tests (RDT) for Ebola, enabling rapid response to public health and bioterrorism threats posed by the deadly virus. Corgenix and the VHFC have previously developed and CE marked the ReLASV® rapid test for the Lassa fever virus. Corgenix CEO Douglass Simpson said that as a reaction to the recent outbreak, the VHFC has shifted most of its efforts to the final phase of activity contemplated by the current NIH grant. Simpson also noted that, contrary to recent reports in the press, Corgenix has not finalized development of the Ebola products. “I want to strongly emphasize that this is a new three-year project, building off work commenced in 2010. We do not currently have an Ebola test nor will we likely have a final one in the near future,” said Simpson. “We understand the critical nature of this virus and are doing everything possible to accelerate efforts to develop reliable and rapid result diagnostic kits in order to be ready for the next outbreak.” According to Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principal Investigator of the VHFC, “This is uncharted territory, and we’re all working with a heightened sense of urgency. Our goal is to be prepared for future outbreaks with rapid, accurate, point-of-care testing to diagnose or rule out both Ebola and Lassa, wherever it occurs, leading to quicker and more effective treatment, thus limiting the spread of the virus.” The Ebola RDT has not yet been approved or cleared for clinical or diagnostic use by any worldwide regulatory authority. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). About the Viral Hemorrhagic Fever Consortium The Viral Hemorrhagic Fever Consortium was established in 2010 as a result of several multi-year grants and contracts awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to support Tulane's ongoing efforts to treat and prevent Lassa fever. The goal of the Consortium is to understand mechanisms related to the human immune response to Lassa virus infection. Specifically, by understanding what parts of the virus are recognized by the immune system, scientists can better understand mechanisms of antibody-mediated protection or pathogenesis in humans with Lassa fever. Consortium efforts have focused on the development of new recombinant proteins for Lassa virus diagnostic products, which have shown to be extremely effective in clinical settings in Africa. This progress is allowing a transition of efforts towards instituting better treatment of affected individuals and ultimately prevention of Lassa fever altogether. The Consortium is a collaboration between Tulane, Scripps Research Institute, Harvard University/Broad, University of Texas Medical Branch, Autoimmune Technologies LLC, Corgenix Medical Corporation, Kenema Government Hospital (Sierra Leone), the Irrua Specialist Teaching Hospital (Nigeria), Université de Lausanne (Switzerland), Zalgen Labs, LLC, and various other partners in West Africa. More information is available at www.vhfc.org. Research detailed in this publication is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI088843. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

CHICAGO--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection,” presented at the conference by Corgenix Research Associate Abby Jones, M.S. The Best Annual Meeting Abstract Award is given by the AACC Critical and Point of Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting. “We’re pleased to accept this prestigious award, and we must also recognize our academic, research and industry partners at the Viral Hemorrhagic Fever Consortium who have helped to make this possible,” said Douglass Simpson, Corgenix President and CEO. “We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats.” Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV® rapid diagnostic test for the Lassa fever virus. Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it’s clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg. On Thursday, July 31, 2014, Corgenix is also presenting an oral abstract titled “Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone.” This first-ever oral abstract for Corgenix will be discussed at 11:30 a.m. during the AACC morning symposia titled “Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections.” The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix will exhibit its AspirinWorks® (11dhTxB2) Test at AACC July 29 to July 31, 2014, in booth No. 3735. Also featured will be the SkyLAB752™ instrument from strategic partner AXA Diagnostics; SkyLAB752 is the fastest automated ELISA instrument for processing the Corgenix AspirinWorks assay. Corgenix will have an additional presence in strategic partner ELITech Group’s booth No. 741 where several Corgenix products will be on display, including the AspirinWorks/11dhTxB2 and Hyaluronic Acid Test Kits. Among its five scientific presentations, Corgenix has been awarded Best Annual Meeting Abstract for AACC 2014 in the Critical and Point of Care Testing Division for Infectious Disease poster B-068 titled “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection.” The company is also presenting an oral abstract of Clinical Studies/Outcomes poster A-143 titled “Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone.” The oral abstract will be presented at 11:30 a.m. during the Thursday, July 31, 2014, morning symposia titled “Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections.” The three additional Corgenix poster abstracts to be presented during AACC 2014 are 1) Cardiac Markers poster B-356: “An Immunoturbidimetric Assay for the Detection of Thromboxane Metabolites in Urine;” 2) Hematology/Coagulation poster A-296: “A Dual Monoclonal Antibody Chemiluminescent ELISA for the Detection of Hepcidin-25;” and 3) Infectious Disease poster B-079: “An Immunoturbidimetric Assay for Hyaluronic Acid.” Corgenix representatives will be available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders. AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11dhTxB2). High levels of 11dhTxB2, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness and therefore reducing the chance of forming a blood clot. Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com. The Hyaluronic Acid Test Kit has not been cleared or approved for diagnostic use in the United States by the U.S. Food and Drug Administration. However, it is CE marked for diagnostic use in the European Union. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website). Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.